Sirapa Klinfueng

Chulalongkorn University — Thailand

Medicine · Health Sciences

20h-index1.2kcitations65works2.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(37), COVID-19 Clinical Research Studies(27), Animal Virus Infections Studies(15), Hepatitis B Virus Studies(13), Hepatitis C virus research(12)

Publications65 total

Age associated SARS-CoV-2 immune responses provide insights into population immunity over four years since the COVID-19 pandemic
Scientific Reports·2025· 4 citedOpen Access
A comparative national survey on the gradual decline of hepatitis C virus prevalence in Thailand, 2004, 2014, and 2024
Scientific Reports·2025Open Access
Seroprevalence of antibodies to hepatitis A, B and C viruses across all age groups in Chonburi Province, Thailand, 2022–2023
Human Vaccines & Immunotherapeutics·2025· 1 citedOpen Access
Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections
Scientific Reports·2025· 6 citedOpen Access
Significant reduction in Hepatitis B virus infections following 32 years of universal Hepatitis B vaccination as part of EPI, Thailand
Scientific Reports·2025· 1 citedOpen Access
Hepatitis B prevalence in an endemic area of hepatitis C virus: A population-based study implicated in hepatitis elimination in Thailand
Journal of Virus Eradication·2024· 2 citedOpen Access
Seroprevalence of antibodies against diphtheria, tetanus, and pertussis across various age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand
Heliyon·2024· 7 citedOpen Access
Persistence of hepatitis B surface antibody until 7 years of age following administration of hexavalent and pentavalent vaccines in children at 2, 4, 6, and 18 months
Vaccine X·2024Open Access
Seroprevalence of antibodies against varicella zoster virus across all age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand
Human Vaccines & Immunotherapeutics·2024· 1 citedOpen Access
Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
Heliyon·2023· 6 citedOpen Access
Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year
Vaccines·2023· 3 citedOpen Access
Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023
Scientific Reports·2023· 15 citedOpen Access
Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma
Diseases·2023· 5 citedOpen Access
SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis
Vaccines·2023· 12 citedOpen Access
Neutralizing antibodies against Omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity
International Journal of Infectious Diseases·2023· 8 citedOpen Access
Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years
Journal of Medical Virology·2023· 4 cited
SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study
PLoS ONE·2023· 17 citedOpen Access
Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: A cross-sectional survey from October 2022 to January 2023
Research Square (Research Square)·2023· 1 citedOpen Access
The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5
Vaccines·2023· 7 citedOpen Access
The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA.4/BA.5
2023· 4 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Yong Poovorawan(50), Preeyaporn Vichaiwattana(41), Nungruthai Suntronwong(35), Thanunrat Thongmee(34), Nasamon Wanlapakorn(32), Natthinee Sudhinaraset(27), Sitthichai Kanokudom(26), Suvichada Assawakosri(25), Donchida Srimuan(24), Chompoonut Auphimai(21), Ritthideach Yorsaeng(21), Jira Chansaenroj(21), Pornjarim Nilyanimit(19), Thaksaporn Thatsanatorn(18), Sompong Vongpunsawad(17), Sittisak Honsawek(12), Lakkhana Wongsrisang(12), Thaneeya Duangchinda(11), Warangkana Chantima(11), Pattarakul Pakchotanon(11)